Audit: QRS - Luteolin for Health & Longevity
Audit conducted on 15/09/2026 05:01 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol, time-to-effect, benefit, risk, contraindication, interaction, biomarker and qualitative entries trace to ER lines 319–358, 382–406, 445, 155–231, 265–299, 477–494. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | time_3_sub keeps “but rest on uncontrolled observation” (ER line 445); at_a_glance keeps “human evidence thinner” and “Safety looks favorable” (ER lines 522, 524). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications; interactions remain interactions; no hedge is removed or added. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from “Populations who should avoid Luteolin”; risks only from Potential Risks & Side Effects; no Benefit-/Risk-Modifying Factor content is surfaced. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Only ER-generic references (“the open-label trial”, “the smell-recovery trials”, “the cardiometabolic trial”) are used. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register carried over from the ER Conclusion and Protocol sections. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Protocol, monitoring targets and qualitative markers give actionable structure while the lede states the evidence limits plainly. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Values are stated descriptively (“Doses above 200 mg are commonly split…”, “Morning with breakfast”), not as orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative clinical instruction; the cadence line reports the ER’s “practical cadence” rather than prescribing one. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommended”, “should”, “advised” in the QRS body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained only where they are the decision gate itself (CYP3A4, carboxylesterase 1, Child-Pugh class), matching ER usage. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk entry is a bare label with no elaboration. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for “you”/”your”; none present. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Nine-marker monitoring panel, functional (not conventional) reference ranges and a 15-item interaction gate presuppose a proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Baseline plus three-month and six-month lab panels and split dosing are presented without any effort caveat. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification to a general-population “just take one capsule” framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede foregrounds the combination-product confound and seller-funded evidence — the weighting this audience needs. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route and form use “purified luteolin, taken with food” and “capsules” as in the ER; the lede phrase “mopping up free radicals” is carried verbatim from ER line 520. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate labels, tier labels and table headers match the template byte-for-byte (lines 440, 477, 519, 537, 552, 579, 594, 598–600, 713). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; the repeatable marker_#* and qualitative_item# spans are expanded to 9 and 6 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Full diff against the template shows changes confined to variable content; head, CSS, structural markup, section comments and footer are identical. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the unpopulated benefit/risk tiers are governed by 12.5 and 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Standard supplement dose”, “Best time of day”, “Single versus split dosing”) and 13 of 15 interaction labels are verbatim; the two trimmed labels are covered by the 9.2 and 9.5 allowances. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; all derive from ER bold labels or ER benefit/risk headings. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan finds no emoji; the ER’s “⚠️ Conflicted” and “⭕️ Not Central” markers are stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to bare labels with no prose; the remaining volume is the completeness floor set by 8.2, 9.2, 12.x, 13.x, 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the comment opens immediately after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” line 3, closing “—” line 13, preceded by the permitted title text on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in head or body markup. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:03" is quoted, correctly so because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: luteolin_2026-0913-0514_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0915-0446, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: luteolin_2026-0913-0514_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user and git_issue; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Luteolin for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Luteolin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/15/2026, correctly derived from qrs_creation_date: 2026-0915-0446. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block (lines 415–428) is structurally identical to the template; no alternate-names line despite the ER carrying five. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs (ER lines 520–526) into the decision-relevant core: mechanism, evidence depth, combination confound, safety, funding bias. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 55 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Sentence 1 → ER line 520; sentence 2 → lines 520/522; sentence 3 → line 522 verbatim; sentence 4 → line 524; sentence 5 → line 526. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “inflammatory signaling”, “free radicals” and “controlled trial” are the ER’s own plain-language terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the “Populations who should avoid Luteolin” list, ER lines 349–358. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 8 ER avoid-items are present, in ER order, with none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements, lines 540–547. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The pregnancy rationale (“no human safety data, and the aromatase and thyroid signals…”) and the hepatic rationale (“where conjugation capacity is reduced”) are both stripped; no dash-trailing clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | TSH thresholds (4.5 / 0.4 mIU/L), Child-Pugh Class B or C, the 14-day surgical window and the 12-month stent window are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in the contraindication list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names eight such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the fifteen bold-labelled interaction bullets, ER lines 319–347. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 15 ER interaction bullets are represented; the aromatase-inhibitor half of the ER line 329 bullet is correctly excluded because it is already a contraindication (QRS line 543). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Fifteen <li> elements, lines 555–569. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “Caution.”/”Monitor.” verdict and every mitigation sentence is stripped; only the labelled entity plus its drug list survives. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named example-drug lists are retained; only the explanatory gloss “agents that clear senescent cells:” is trimmed from the senolytic entry, within the allowance. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in the interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names fifteen such interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets derive from Therapeutic Protocol, ER lines 382–406. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and dosing frequency — the three decisions a reader must make before taking the compound. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains sixteen bullets; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields populated; action_1_sub additionally carries the over-65 range from ER line 406, which sits in the same Protocol section. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Smell recovery, cardiometabolic markers and histamine-related symptoms — exactly the three horizons the ER gives at line 445. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Smell recovery (Medium) → cardiometabolic markers (Medium) → histamine-driven symptoms (Speculative), matching the ER’s own benefit tiering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; each sub is near-verbatim from ER line 445, including the “uncontrolled observation” caveat. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All entries map one-to-one onto ER benefit headings, lines 149–231. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 521–530. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; every Magnitude paragraph is omitted. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any benefit tier. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER states no benefit reaches High (line 151); benefits_high is emptied and set to style="display: none" at line 521. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Both populated tiers map onto ER risk headings, lines 255–299. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 581–588. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; the 54% frequency and the 1–8 week duration are omitted as required. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in either populated tier. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER states no risk reaches High or Medium (lines 257, 261); both spans are emptied and set to style="display: none" at lines 581–582. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from Monitoring Protocol & Defining Success, ER lines 471–485. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER table rows appear as marker_1 through marker_9, in ER order, with targets and rationales intact. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 707 carries the baseline / three-month / six-month / annual cadence from ER lines 471 and 473. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the qualitative-marker list at ER lines 489–494. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers appear verbatim as qualitative_item_1 through qualitative_item_6. |
Issues 15/09/2026 05:01
Pass rate 100.00%. No issues found.
Issues 15/09/2026 04:52
- 12.3 / 12.4 — Parenthetical qualifier in Benefits: The Medium benefits item at line 523 reads “Recovery of smell after viral olfactory loss (conflicted)”, carrying the ER’s “⚠️ Conflicted” flag through as a parenthetical qualifier, which items 12.3 and 12.4 require to be stripped; the equivalent “⭕️ Not Central to Health & Longevity” flag on the autism item was correctly dropped.
Fixes 15/09/2026 04:52
- 12.3 / 12.4 — Parenthetical qualifier in Benefits: Removed “(conflicted)” from the first Medium benefits item, changing it from “Recovery of smell after viral olfactory loss (conflicted)” to “Recovery of smell after viral olfactory loss”.